Background: Controversies remain as to the differential diagnosis between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IM) in lung cancers. We have investigated the clinical criteria for MPLC and here propose a set of new and simple criteria from the stand point of prognosis. Methods: A retrospective study was conducted on 588 consecutive patients with resected lung cancer of clinical Stage IA between 2009 and 2012. Multiple lung cancers (MLCs) were observed in 103 (17.5%) of the 588 patients. All main and other tumors were divided into solid tumor (ST) and non-solid tumor (non-ST). We defined Group A as MLCs having at least one non-ST and Group B as all tumors being ST. Cox's proportional hazard model was used for the multivariate analyses to investigate the preoperative prognostic factors. We divided the MLCs into MPLC and IM based on the preoperative prognostic factors, and survival was estimated by the Kaplan-Meier method. Results: A multivariate analysis with Cox's proportional hazards model revealed that Group A independently predicted good overall survival (HR = 0.165, 95% CI: 0.041-0.672).Differences in the 3-and 5-year overall survivals between Groups A and B were statistically significant (96.3%/92.2% vs. 70.0%/60.0%, P value = 0.0002). Conclusions: We suggest that Group A, defined as the presence of at least one tumor with a ground glass opacity component and clinical N0, should be excluded from the conventional concept of multiple lung cancers based on the criteria of Martini and Melamed as it has a very good prognosis. This group would be considered to be radiological MPLC.
Introduction
Martini and Melamed proposed the criteria for diagnosing multiple primary lung cancer (MPLC) based on pathological features and became the standard used by clinicians and pathologists ever since the original publication in 1975, due to their ease of application (1-7). Antakli et al. modified the original Martini and Melamed criteria by adding premalignant lesions and DNA ploidy. With regard to DNA ploidy, a different ploidy pattern was suggested as an indicator of a different tumor cell origin. However, one must stress that a different DNA ploidy pattern does not exclude the possibility of the same tumor cell origin. This is due to the heterogeneity of the DNA ploidy within the same tumor and also the change in the ploidy pattern that accompanies tumor progression. In 2007, the American College of Chest Physicians updated the diagnostic criteria by adding additional clinical assessment molecular genetic characteristics and so on (8) (9) (10) .
However, even understanding the definition of MPLC was a challenge due to the extreme difficulty in distinguishing MPLC and intrapulmonary metastasis (IM). In this modern era in particular, we encounter two contradictory problems. One is that although we can investigate the status of the molecular/genetic profile, MPLC has become more complex (11) . The other is the increasing opportunities to detect small or faint lung nodules such as ground glass nodules (GGN), which could be diagnosed as lung cancer radiologically, as computed tomography (CT) has become more widely used (12) (13) (14) (15) (16) (17) .
In practice, criteria based not on pathological or molecular status, but on clinical information are needed to decide the appropriate treatment strategy for MPLC including small sized nodules or nodules with a ground glass opacity (GGO) component. Thus, we investigated the preoperative criteria for MPLC and here propose a set of new and simple radiological criteria from the stand point of prognosis.
Methods

Study population
A retrospective study was conducted on 588 consecutive patients with resected lung cancer of clinical Stage IA between January 2009 and October 2012. As we investigated the prognosis of clinical MPLC and IM, we excluded cT2 or cT3 tumors which could have occult nodal involvements. Because these nodal involvements could be worse prognostic factors than IM. All patients underwent preoperative thinsection CT and the authors reviewed the radiological findings for all cohorts. We defined multiple lung cancers (MLCs) as a primary lung cancer having additional tumors that were detected on thin-section CT in synchronous or as secondary lung cancer in patients who had undergone lung resection for primary lung cancer in metachronous. MLCs were observed in 103 (17.5%) of the 588 patients. At the same time, there were two cases which eventually had the diagnosis as benign disease pathologically after the second targeted lesion was resected. Pathologically, one was a hyperplasia of lymph node and another was an organizing pneumonia. All tumors were divided into solid tumor (ST) and non-solid tumor (non-ST) according to the presence of a GGO component based on findings of thin-section CT, indicating that ST had no GGO component (Fig. 1) . So, if a tumor had slightly GGO component, it was classified as non-ST, and if one consisted of only solid component, it was did as ST. Thin-section CT was performed to evaluate the entire lung with a collimation of 1-2 mm. The lung was photographed with a window level of −500 to −700 Hounsfield units (HU) and a window width of 1500-2000 HU as the lung window. In this study, synchronous multiple lung cancers (sMLCs) were observed in 89 patients. Among them, there were 26 patients in whom the main tumor was resected and diagnosed as nonsmall cell lung cancer (NSCLC) pathologicallyand more than one other tumor was diagnosed radiologically as lung cancer as it consisted solely of a GGO component with almost no change in size for at least 6 months. Length of survival was defined as the interval from the day of surgical intervention to the date of the last follow-up. Metachronous multiple lung cancers (mMLCs) were observed in 14 patients and secondary lung cancers were resected as clinical Stage IA NSCLC between January 2009 and October 2012. Both primary and secondary lung cancers were diagnosed as NSCLC pathologically. In mMLCs, the length of survival was defined as the interval from the day of surgical intervention for secondary lung cancer to the date of the last follow-up. This is because in practice, it is important to resect secondary lung cancers as MPLC or IM when encountered. Among the patients, two that had a third lung cancer underwent surgical resection.
Treatment strategy
The main tumor was selected according to the grade of malignancy shown radiologically in sMLCs. Thus, we initially chose ST as the main tumor if a ST was present. If more than two STs were present, the largest was selected as the main tumor. Next, if all the tumors were non-ST, the tumor with the smallest ratio of GGO component was selected as the main tumor. In MLCs, lobectomy with systematic lymph node dissection was performed for the main tumor and ST, and sublobar resection was performed for the non-solid additional nodules. However, there were no clear-cut criteria regarding the appropriate operative procedure to use as we needed to consider several clinical factors such as the location of tumor, radiological findings, estimated postoperative respiratory function, cardiac function, performance status and so on. sMLCs located on the ipsilateral side were resected in one-stage surgery and those located on the contralateral side were basically resected in a two-stage surgery within 6 months. We tried to resect tumors consisting solely of a GGO component larger than 10 mm. However, some tumors that could not be resected were monitored closely due to the same clinical factors mentioned above. Tumors that consisted solely of a GGO component less than 10 mm were not resected but monitored closely.
Study design
We defined Group A as MLCs having at least one non-ST and Group B as all tumors being ST (Fig. 2) . We tried to divide the MLCs into MPLC and IM based on the preoperative prognostic factors.
Statistical analysis
Chi-square test and Fisher's exact test were used to compare two factors. Cumulative survival was estimated with a Kaplan-Meier model. Survival rates were compared by log-rank test. Univariate analyses were performed by log-rank test and Cox's proportional hazard model was used to identify the prognostic factors in multivariate analysis. A probability value of less than 0.05 was set as the cut-off point for selecting variables for the multivariate analysis. All statistical calculations were performed using StatView Version 5.0 statistical software (SAS Institute Inc., Cary, NC).
Results
Patients' characteristics and surgical procedures
There were 37 men and 66 women who ranged in age from 40 to 84 years (median 67 years). Table 1 shows that the frequency of women and sMLCs in Group A was significantly higher than in Group B (P value = 0.004 and 0.0004). There were no statistical differences between Groups A and B regarding the other clinical factors. Furthermore, there was no statistical difference between the two groups regarding the distribution of surgical mode, histological type, pathological stage and epidermal growth factor receptor (EGFR) mutations, however, in Group A the incidence of pathological Stage I and EGFR mutant tended to be higher than in Group B. Among the patients, 37 (35.9%) underwent a combination procedure of lobectomy and sublobar resection. In this study, there was no pneumonectomy or completion pneumonectomy, and lobectomy in bilateral surgery was performed for only four patients.
Mortality and recurrences
Overall 30-and 90-day mortalities were both 0.97%, and only one patient died of an unknown cause. There were only two deaths that were due to causes other than lung cancer. One patient died at home of an unknown cause on postoperative Day 29. This patient underwent lobectomy and segmentectomy for metachronous MLCs. The other patient died of heart failure 3 years after undergoing surgical resection and experiencing a relapse. Furthermore, there was no locoregional relapse. There were 14 relapse patients, 10 of whom had distant metastases such as bone metastasis and brain metastasis. Two patients had recurrence of the mediastinal and subclavian lymph nodes and one had multiple bilateral pulmonary metastases. Only one patient had ipsilateral pulmonary metastasis, so she underwent surgical resection completion right S6 segmentectomy after right upper lobectomy.
Overall survival and preoperative prognostic factors
Overall 3-and 5-year survival rates were 93.7% and 88.6%, respectively, and the median follow-up was 46.1 months. The overall 5-year survival rate in female, non-heavy smoker and clinical T1a was significantly better than that for male, heavy smoker and clinical T1b (P value = 0.029/0.012/0.019). While the difference in overall 5-year survival between Groups A and B was statistically significant (92.2% vs. 60.0%, P value = 0.0002), no significant difference was found between sMLCs and mMLCs (89.0% vs. 85.7%, P value = 0.443) ( Table 2 ). Multivariate analysis with Cox's proportional hazard model revealed that Group A independently predicted good overall survival (Table 3 ). Figure 2 shows the overall survival curves for Groups A and B.
Discussion
We have developed a new set of simple criteria for radiological multiple primary lung cancer in modern era. In our study, Group A was a good preoperative prognostic factor in multivariate analysis and Figure 2 . The differences in the 3-and 5-year overall survivals between Groups A and B were statistically significant (96.3%/92.2% vs. 70.0%/60.0%, P value = 0.0002). the differences in the 3-and 5-year overall survivals between Groups A and B were statistically significant (96.3%/92.2% vs. 70.0%/60.0%, P value = 0.0002). Thus, we suggest that Group A, defined as having at least one tumor with a GGO component and clinical N0, should be excluded from the conventional concept of MLCs based on the criteria of Martini and Melamed as it has a very good prognosis (1) (2) (3) (4) (5) (6) (7) . This group was thought to be clinical MPLC and a suitable candidate for local treatment such as surgery. While the criteria of Martini and Melamed needs the pathological status such as histologic type, nodal involvement of common lymphatic pathway or carcinoma in situ, recently small-sized lung cancers tend to be detected as CT has become more widely used, and adenocarcinoma, which frequently displays radiological and histological heterogeneity, has replaced squamous cell carcinoma as the most common histologic subtype (18, 19) . This has been accompanied by more frequent encounters with MLCs including GGO. In fact, the frequency of MLCs was 17.5% in this study even though the reported rate in conventional papers on MLCs is 1-7.6% (1-7). Radiological findings of adenocarcinoma varied much, such as pure GGO, GGO predominant part solid tumor, consolidation predominant part solid tumor, scattered consolidation part solid tumor and pure solid tumor. In addition, our groups have revealed the relationship between radiological and pathological findings of these tumors as preoperative sampling of these tumors is a challenge due to their small size (12) (13) (14) (15) (16) (17) . In practice, pathological findings of MLCs need to be predicted from the radiological ones; however, there are cases where distinguishing between MPLC and IP is difficult, such as for pure solid tumors (CTR = 1) or solid component predominant tumors (0.5 < CTR < 1). As such, we could determine the appropriate treatment strategy using our radiological criteria without considering the criteria of Martini and Melamed and could determine the appropriate treatment strategy. Asamura et al. reported that when a consolidation/tumor ratio of 0.5 or less in cT1a-b was used as the cut-off, the 5-year overall survivals of radiologic noninvasive and invasive adenocarcinomas were 96.7% and 88.9%, respectively (P value < 0.001) (20) . In addition, Shimada et al. reported the radiological criteria of a CTR 0.5 as the cut-off in their study based on the results of several reports and compared the prognosis between the GG-group (CTR ≤ 0.5) and GS-group (CTR > 0.5) in MLCs (21) . However, we thought that this cut-off value was a significant problem because the prognosis of the 5-year survival of pure GGNs (CTR = 0) is very good, being 100%, and furthermore the prognosis of all partsolid tumors (0 < CTR < 1) could be also very good as has been reported by our group (22, 23) . On the other hand, pure solid tumors (CTR = 1) may have an occult pN1 or N2, which likely worsens the prognosis (13, 15, 17) . Thus, this study was designed based on our understanding that a tumor having a GGO component even only slightly on thin-section CT could be a primary lesion under any circumstance from the stand point of prognosis, and that MLCs such as Group A could be a multiple primary lung cancer. Furthermore, Group A included MLCs which had ST and PST, and these MLCs had a good prognosis. In this study, these MLCs were observed in 13 patients. Because we think in these group, PST did not affected prognosis and only ST did it, these MLCs would be equivalent to only a solitary tumor in c-Stage IA. And in Group A the incidence of EGFR mutant tended to be higher than in Group B (47.3% vs. 20.0%, P value = 0.179). This may affect the prognosis. We were therefore correct in thinking that our results proved our hypothesis.
Lung cancer with the GGO component was such a significant issue in Asian countries that most published clinical data on this condition were derived from Asian populations. However, recently there was a North American report stating that a predominantly Caucasian group of patients with apparent multifocal lepidic-type adenocarcinoma of the lung harboring a single Stage I or II dominant tumor had an extremely high medium-term survival and disease-free survival following surgical therapy alone. The report also stated that small GGO components left unresected in such a setting progress only very slowly and rarely require intervention (24) . The above report supported our suggestion that our criteria for MLCs is likely appropriate not only for Asians but also for other races worldwide.
Mode of surgery was one of the major problems in the treatment strategy for MLCs due to the limited capacity of the lung parenchyma. In this study, the value for both the 30-and 90-day mortalities was 0.97% and the mortality rate was acceptable compared with the rate of 1.1-8% in the literature (1-7) . Thus, we considered our surgical strategy acceptable from the viewpoints of mortality and recurrence pattern, which were mentioned in the result section. For MPLC in modern era, we must consider preservation of lung parenchyma and the surgical margin for the grade of malignancy of each tumor based on radiological findings. As such, we need to combine not only lobectomy but also segmentectomy and wedge resection such as bisegmentectomy. In this study, the main procedure was segmentectomy that was performed for 14 cases and other procedure was wedge resection or double wedge resection.
This study has strengths and limitations. The strengths are the fact that this is the first report suggesting a set of new and simple criteria for radiological multiple primary lung cancers. Moreover, the criteria are important in this modern era where multiple lung lesions having a GGO component are encountered. Our study was limited by being retrospective, from a single institution, and involved a small sample size. In particular, there were only ten patients in Group B; our focus however, was on Group A and our conclusion was appropriate. Group B seemed to have another problem its 5-year survival in this study was~60% and our surgical treatment was appropriate. The number of patients in Group B was too small and there could have been a selection bias. MLCs with the clinical N0M0 such as that found in Group B are not always good candidates for local treatment, because in general the prognosis of lung cancer with c-T4N0M0 Stage IIIA or cT1N0M1a Stage IV was 6-36% (25) . As other limitations, the median follow-up time was short for tumors having a GGO component because they have a good and long prognosis. Next, the strategy for pure GGN was controversial as most pure GGNs are adenocarcinomas in situ. Some oncologists may say that we need not resect these tumors, but clinically these tumors continue to grow slowly. Furthermore, a few of these tumors grow to become aggressive tumors (26) (27) (28) . These days, however, we cannot mention clinical multiple primary lung cancers except those with a pure GGO or tumors having a GGO component.
In conclusion, We think that Group A, defined as having at least one tumor with a GGO component and clinical N0, should be excluded from the conventional concept of multiple lung cancers based on the criteria of Martini and Melamed as they have a very good prognosis. We could consider this group to be radiological MPLC.
